JP Morgan recently initiated coverage on Exponent with an Overweight/Buy rating, highlighting the firm’s position as a ...
If you are wondering whether Exponent is fairly priced or offering value right now, you are in the right place for a clear, ...
StockStory.org on MSN
Exponent’s (NASDAQ:EXPO) Q4 CY2025: Strong sales
Scientific consulting firm Exponent (NASDAQ:EXPO) reported in Q4 CY2025, with sales up 19.1% year on year to $147.4 million. Its GAAP profit of $0.49 per share was 3.7% above analysts’ consensus ...
Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...
Good day, and welcome to the Exponent, Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results